Stopping a cancer trial is either a very good, or very bad thing – and luckily for Ipsen the former was the case after a liver cancer trial of its Cabometyx pill was curtailed because of th
Syndax Pharmaceuticals has announced a new collaboration with Roche’s Genentech unit dedicated to combining small molecule cancer drug entinostat with the latter’s immunotherapy, Tecentriq.
